In conclusion, despite that no significant differences were observed in IT-based regimens in lung cancer patients according to the type of KRAS mutation (G12C vs. non-G12C), efforts to find novel predictive biomarkers in addition to PD-L1 for KRAS mutant patients will help to tailor treatment in this specific population and offer them rationally designed therapeutic strategies combining both IT-based regimens with targeted therapy. The gene discussed is KRAS; the disease is lung cancer.